Global CAR-T Cell Therapy treatment Market – Industry Trends and Forecast to 2030

Personalice su informePersonalice su informe Compre ahoraCompre ahora Ejemplo de informe gratuitoEjemplo de informe gratuito
Hogar Pharmaceutical Global Car T Cell Therapy Treatment Market
Solicitud de índiceSolicitud de índice Hable con el analistaHable con el analista Comprar ahoraComprar ahora Consultar antes de comprarConsultar antes Informe de muestra gratuitoInforme de muestra gratuito

Global CAR-T Cell Therapy treatment Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Sep 2023
  • Global
  • 350 Páginas
  • Número de tablas: 220
  • Número de figuras: 60
Comprar ahoraComprar ahora

Global Car T Cell Therapy Treatment Market

Tamaño del mercado en miles de millones de dólares

Tasa de crecimiento anual compuesta (CAGR) :  % Diagram

Diagram Período de pronóstico
 2024 –2030
Diagram Tamaño del mercado (año base)
 MILLONES DE DÓLARES
Pedido
Diagram Tamaño del mercado (año de pronóstico)
 MILLONES DE DÓLARES
Solicitud de desbloqueo
Diagram Tasa de crecimiento anual compuesta (CAGR)
 %
Diagram Jugadoras de los principales mercados
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5
Solicitud de desbloqueo

>Mercado global de tratamiento con terapia de células CAR-T, por producto (células CAR-T autólogas, células CAR-T alogénicas), estructura (células CAR-T de primera generación, células CAR-T de segunda generación, células CAR-T de tercera generación, células CAR-T de cuarta generación), antígenos dirigidos (antígenos en tumores sólidos, antígenos en neoplasias hematológicas, otros), marca (Yescarta, Kymriah, Tecartus, otros), aplicación terapéutica (neoplasias hematológicas, cáncer de páncreas, cáncer de mama, cáncer de pulmón, cáncer gástrico, mieloma múltiple , leucemia linfocítica crónica, linfoma de células del manto, linfoma folicular, linfoma difuso de células B grandes, leucemia linfoblástica aguda, otros), usuario final (hospitales, clínicas especializadas, otros), canal de distribución (farmacias de hospitales, otros) - Tendencias de la industria y pronóstico hasta 2030.

CAR-T Cell Therapy Treatment Market

 Análisis y tamaño del mercado de tratamiento con terapia de células CAR-T

La terapia con células CAR-T o células T con receptores de antígenos quiméricos son aquellas células T que se modifican genéticamente para producir un receptor de células T artificial que se puede utilizar como inmunoterapia para el tratamiento de diversos tipos de cáncer. Los receptores de antígenos quiméricos son aquellas proteínas receptoras que se han modificado en los laboratorios para proporcionar a las células T la novedosa capacidad de dirigirse a una proteína específica.

Data Bridge Market Research analiza el mercado de tratamiento con terapia de células CAR-T, que se espera que experimente una CAGR del 32,3 % durante el período de pronóstico de 2023 a 2030. Las "células CAR-T autólogas" dominan el segmento de productos del mercado de tratamiento con terapia de células CAR-T debido al auge de las industrias farmacéuticas. Además de los conocimientos sobre escenarios de mercado, como el valor de mercado, la tasa de crecimiento, la segmentación, la cobertura geográfica y los principales actores, los informes de mercado seleccionados por Data Bridge Market Research también incluyen un análisis profundo de expertos, epidemiología de pacientes, análisis de cartera, análisis de precios y marco regulatorio.

Alcance y segmentación del mercado de tratamiento con terapia de células CAR-T

Métrica del informe

Detalles

Período de pronóstico

2023 a 2030

Año base

2022

Años históricos

2021 (Personalizable para 2015-2021)

Unidades cuantitativas

Ingresos en millones de USD, volúmenes en unidades, precios en USD

Segmentos cubiertos

Producto (células CAR-T autólogas, células CAR-T alogénicas), estructura (células CAR-T de primera generación, células CAR-T de segunda generación, células CAR-T de tercera generación, células CAR-T de cuarta generación), antígenos específicos (antígenos en tumores sólidos, antígenos en neoplasias hematológicas, otros), marca (Yescarta, Kymriah, Tecartus, otros), aplicación terapéutica ( neoplasias hematológicas , cáncer de páncreas, cáncer de mama, cáncer de pulmón, cáncer gástrico , mieloma múltiple, leucemia linfocítica crónica, linfoma de células del manto, linfoma folicular, linfoma difuso de células B grandes, leucemia linfoblástica aguda, otros), usuario final (hospitales, clínicas especializadas, otros), canal de distribución (farmacias de hospitales, otros)

Países cubiertos

EE. UU., Canadá, México, Alemania, Reino Unido, Francia, Italia, España, Países Bajos, Rusia, Suiza, Bélgica, Turquía, Austria, Noruega, Hungría, Lituania, Irlanda, Polonia, Resto de Europa, Japón, China, Australia, India, Corea del Sur, Singapur, Indonesia, Tailandia, Malasia, Filipinas, Vietnam, Resto de Asia-Pacífico, Brasil, Argentina, Perú, Resto de Sudamérica, Arabia Saudita, Sudáfrica, Emiratos Árabes Unidos, Israel, Kuwait, Egipto y Resto de Medio Oriente y África.

Actores del mercado cubiertos
  • Autolus (Reino Unido), Atara Biotherapeutics, Inc. (EE. UU.), Amgen Inc. (EE. UU.), Bellicum Phamaceuticals, Inc. (EE. UU.), bluebird bio, Inc. (EE. UU.), Adaptimmune Therapeutics plc (Reino Unido), Bristol-Myers Squibb Company (EE. UU.), Xyphos (una subsidiaria de Astellas Pharma Inc.) (EE. UU.), Johnson & Johnson Services, Inc. (EE. UU.), BioAtla Inc. (EE. UU.), AbbVie Inc. (EE. UU.), Novartis AG (Suiza), Kite Pharma (una subsidiaria de Gilead Sciences, Inc.) (EE. UU.), Aurora Biopharma (EE. UU.), Tmunity Therapeutics (EE. UU.), Cartherics pty. Ltd (Australia), CARINA BIOTECH (Australia), Ziopharm Oncology, Inc. (EE. UU.), Cellectis SA (Francia), Mustang Bio (EE. UU.), Sorrento Therapeutics, Inc. (EE. UU.), Cartesian Therapeutics, Inc. (EE. UU.), TC BioPharm Limited (Reino Unido), Celyad Oncology SA (Bélgica), Tessa Therapeutics Ltd. (Singapur)

Oportunidades de mercado
  • Creciente demanda de medicina personalizada
  • Mercado emergente con expansión

Definición de mercado

El tratamiento con células T con receptores de antígenos quiméricos, a menudo conocido como terapia de células T CAR, es una estrategia de inmunoterapia revolucionaria que se utiliza para tratar cánceres específicos. Para expresar un receptor de antígenos quiméricos (CAR) en su superficie, es necesario alterar genéticamente las propias células T del paciente, un subtipo de célula inmunitaria. El objetivo de este receptor modificado es atacar antígenos específicos presentes en las células cancerosas.

Dinámica del mercado de tratamiento con terapia con células CAR-T

Conductores

  • Creciente prevalencia de terapias dirigidas

Las terapias con células T CAR han sido posibles gracias al desarrollo de la medicina de precisión y de terapias dirigidas. Estas terapias minimizan el daño a los tejidos sanos y reducen los efectos adversos al dirigirse a antígenos específicos de las células cancerosas.

  • Avances tecnológicos en aumento

Las herramientas de edición genética , como CRISPR/Cas9, han mejorado el diseño y la personalización de los tratamientos con células T CAR, aumentando su seguridad y eficacia. Estas mejoras continuas en las técnicas de ingeniería celular

  • Aumento de la financiación por parte de las autoridades públicas y privadas

Tanto fuentes públicas como privadas han realizado inversiones considerables en el negocio de la terapia con células T CAR. El desarrollo de nuevas curas y tecnologías se ha acelerado gracias al apoyo financiero para la investigación y el desarrollo.

Oportunidades

  • Demanda creciente de medicina personalizada

La creación de terapias personalizadas con células T CAR adaptadas a pacientes específicos es posible gracias a los avances en la investigación genómica y de biomarcadores. Esta estrategia puede dar lugar a tratamientos más especializados, eficientes y con menos efectos adversos

  • Mercado emergente en expansión

There are no geographical restrictions on CAR T-cell treatments. If businesses can manage legislative variations and market specific obstacles, opening up the market to more nations and regions offers significant growth prospects

Restrains/ Challenges

  • Strict Regulations

Living cells are frequently manipulated during cell treatments, which provides special regulatory difficulties. Due to the importance of ensuring the efficacy and safety of these medicines, strict regulatory procedures must be followed. Overcoming these regulatory barriers may cause market entry to be delayed and development expenses to rise

  • High Development Costs

The process of creating cell treatments is time consuming and expensive. The expenditures can be unreasonably costly for everything from research and clinical trials to manufacturing and regulatory approvals. As a result, there may be fewer businesses ready to invest in the development of cell therapies, which could raise the price of patient care

  • Long Term Safety and Efficacy

Due to the relatively recent development of cell therapies, there are frequently few long-term safety and efficacy data available. Building confidence among healthcare professionals, payers, and patients requires regular monitoring and evaluation of patients undergoing cell treatments

This  CAR-T cell therapy treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the CAR-T cell therapy treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth

Global CAR-T Cell Therapy Treatment Market Scope

The CAR-T cell therapy treatment market is segmented on the basis of the product, structure, targeted antigens, brand, therapeutic application, end-user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Product

  • Autologous CAR-T Cells
  • Allogeneic CAR-T Cells

Structure

  • First Generation CAR-T Cells
  • Second Generation CAR-T Cells
  • Third Generation CAR-T Cells
  • Fourth Generation CAR-T Cells

Targeted Antigens

  • Antigens on Solid Tumors
  • Antigens on Hematologic Malignancies
  • Others

Brand

  • Yescarta
  • Kymriah
  • Tecartus
  • Others

Therapeutic Application

  • Hematological Malignancies
  • Pancreatic Cancer
  • Breast Cancer
  • Lung Cancer
  • Gastric Cancer
  • Multiple Myeloma
  • Chronic Lymphocytic Leukemia
  • Mantle Cell Lymphoma
  • Follicular Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Acute Lymphoblastic Leukemia
  • Others

End-User

  • Hospitals
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospitals Pharmacy
  • Others

 CAR-T Cell Therapy Treatment Market Regional Analysis/Insights

Global CAR-T cell therapy treatment market is analyzed and market size information is provided on basis of product, structure, targeted antigens, brand, therapeutic application, end-user and distribution channel as referenced above.

The countries covered in the global CAR-T cell therapy treatment market report are the U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Netherlands, Russia, Switzerland, Belgium, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, rest of Europe, Japan, China, Australia, India, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, Saudi Arabia, South Africa, U.A.E., Israel, Kuwait, Egypt and rest of Middle East and Africa

The North America is dominating in the global CAR-T cell therapy treatment market and is expected to grow with the highest growth rate in the forecast period of 2023 to 2030 because of increasing healthcare expenditure and well established healthcare infrastructure for the autologous CAR-T cells segment. Asia-Pacific is leading the growth of the global CAR-T cell therapy treatment market and autologous CAR-T cells segment is dominating in the country due to increase in research regarding CAR-T cell therapy treatment.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

CAR-T cell therapy treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and CAR-T Cell Therapy Treatment Market Share Analysis

The CAR-T cell therapy treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to global API intermediates market.

Some of the major players operating in the CAR-T cell therapy treatment market are:

  • Autolus (U.K.)
  • Atara Biotherapeutics, Inc. (U.S.)
  • Amgen Inc. (U.S.)
  • Bellicum Phamaceuticals, Inc. (U.S.)
  • bluebird bio, Inc. (U.S.)
  • Adaptimmune Therapeutics plc (U.K.)
  • Bristol-Myers Squibb Company (U.S.)
  • Xyphos (a subsidiary of Astellas Pharma Inc.) (U.S.)
  • Johnson & Johnson Services, Inc. (U.S.)
  • BioAtla Inc. (U.S.)
  • AbbVie Inc. (U.S.)
  • Novartis AG (Switzerland)
  • Kite Pharma (a subsidiary of Gilead Sciences, Inc.) (U.S.)
  • Aurora Biopharma (U.S.)
  • Tmunity Therapeutics (U.S.)
  • Cartherics pty. Ltd (Australia)
  • CARINA BIOTECH (Australia)
  • Ziopharm Oncology, Inc. (U.S.)
  • Cellectis SA (France)
  • Mustang Bio (U.S.)
  • Sorrento Therapeutics, Inc. (U.S.)
  • Cartesian Therapeutics, Inc. (U.S.)
  • TC BioPharm Limited (U.K.)
  • Celyad Oncology SA (Belgium)
  • Tessa Therapeutics Ltd. (Singapore)

SKU-

Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo

Sample Image Click on image to enlarge
  • Panel de análisis de datos interactivo
  • Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
  • Acceso de analista de investigación para personalización y consultas
  • Análisis de la competencia con panel interactivo
  • Últimas noticias, actualizaciones y análisis de tendencias
  • Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Solicitud de demostración

Tabla de contenido

  1. introduction
    1. OBJECTIVES OF THE STUDY
    2. MARKET DEFINITION
    3. OVERVIEW of GLOBAL CAR-T cell therapy treatment MARKET
    4. LIMITATIONs
    5. MARKETS COVERED
  2. MARKET SEGMENTATION
    1. MARKETS COVERED
    2. geographical scope
    3. years considered for the study
    4. currency and pricing
    5. DBMR TRIPOD DATA VALIDATION MODEL
    6. MULTIVARIATE MODELLING
    7. PRODUCT LIFELINE CURVE
    8. primary interviews with key opinion leaders
    9. DBMR MARKET POSITION GRID
    10. vendor share analysis
    11. MARKET product COVERAGE GRID
    12. secondary sourcEs
    13. assumptions
  3. EXECUTIVE SUMMARY
  4. premium insight
  5. Epidemiology
  6. Pipeline analysis
  7. Market Overview
    1. Drivers
      1. increase in usage of CAR-T CELL THERAPY for the treatment of cancer and infectious diseases
      2. increasing prevalEnce of cancer
      3. rise in awareness about immunotherapies
      4. increasing investment in research and development
      5. adoption of CAR-T cell therapy treatment in Emerging markets
    2. restraints
      1. adverse side effects of therapies
      2. high cost associated with therapies
      3. logistic challenge associated with CAR-T therapies
      4. availability of alternatives for tumor treatment
    3. opportunities
      1. presence of pipeline producTs
      2. strategiC initiatives by market players
      3. Rise in expenditure in healthcare sector
    4. challenges
      1. long approval time for immunotherapies
      2. lack of skilled professionals
  8. IMPACT OF COVID-19 ON GLOBAL CAR-T CELL THERAPY TREATMENT MARKET
    1. IMPACT ON PRICE
    2. IMPACT ON DEMAND
    3. IMPACT ON SUPPLY CHAIN
    4. STRATEGIC DECISION FOR MANUFACTURERS
    5. CONCLUSION
  9. global CAR-T Cell Therapy Treatment MARKET, BY PRODUCT
    1. overview
    2. Autologous CAR-T Cells
    3. Allogeneic CAR-T Cells
  10. global CAR-T CELL THERAPY TREATMENT MARKET, BY Structure
    1. overview
    2. First Generation CAR-T Cells
    3. Second Generation CAR-T Cells
    4. Third Generation CAR-T Cells
    5. Fourth Generation CAR-T Cells
  11. global CAR-T CELL THERAPY TREATMENTMARKET, BY Targeted Antigens
    1. overview
    2. Antigens on Hematologic Malignancies
      1. Cluster of Differentiation-19 (CD-19)
      2. Cluster of Differentiation-30 (CD-30)
      3. Cluster of Differentiation-22 (CD-22)
      4. Cluster of Differentiation-20 (CD-20)
      5. Cluster of Differentiation-33 (CD-33)
    3. Antigens on Solid Tumors
      1. Human Epidermal Growth Factor Receptor-2 (HER-2)
      2. Epidermal Growth Factor Receptors Variant III (EGFRV-III)
      3. Mesothelin (MSLN)
      4. Prostate-Specific Membrane Antigen (PSMA)
      5. Interleukin-13RA2 (IL13RA2)
      6. Disialoganglioside 2 (GD2)
      7. Glypican-3 (GPC3)
      8. Others
    4. OTHERS
  12. global CAR-T cell therapy treatment MARKET, BY brand
    1. overview
    2. yescarta
    3. KYMRIAH
    4. TECARTUS
    5. others
  13. global CAR-T cell therapy treatment MARKET, BY therapeutic application
    1. overview
    2. Follicular Lymphoma
    3. Diffuse Large B-Cell Lymphoma
    4. Acute Lymphoblastic Leukaemia (ALL)
    5. Mantle Cell Lymphoma
    6. Multiple Myeloma
    7. Hematologic Malignancies
      1. Leukemia
      2. Lymphoma
      3. Myeloma
      4. Others
    8. Lung Cancer
    9. Chronic Lymphocytic Leukemia
    10. Gastric Cancer
    11. Pancreatic Cancer
    12. Breast Cancer
    13. others
  14. global CAR-T cell therapy treatment MARKET, BY end user
    1. overview
    2. hospitals
    3. Specialty Clinics
    4. others
  15. global CAR-T cell therapy treatment MARKET, BY distribution channel
    1. overview
    2. hospital Pharmacy
    3. others
  16. Global CAR-T cell therapy treatment market by geography
    1. Overview
    2. NORTH AMERICA
      1. U.S
      2. Canada
      3. Mexico
    3. EUROPE
      1. germany
      2. u.k
      3. France
      4. Italy
      5. Spain
      6. NETHERLANDS
      7. Russia
      8. Switzerland
      9. Belgium
      10. Turkey
      11. Austria
      12. Norway
      13. Hungary
      14. Lithuania
      15. Ireland
      16. Poland
      17. Rest of Europe
    4. ASIA-PACIFIC
      1. japan
      2. Australia
      3. Singapore
      4. China
      5. South Korea
      6. INDIA
      7. Malaysia
      8. Thailand
      9. Indonesia
      10. Philippines
      11. Vietnam
      12. rest of asia-pacific
    5. SOUTH AMERICA
      1. BRAZIL
      2. aRGENTINA
      3. PERU
      4. REST OF SOUTH AMEERICA
    6. MIDDLE EAST AND AFRICA
      1. sAUDI ARABIA
      2. UAE
      3. SOUTH AFRICA
      4. ISRAEL
      5. KUWAIT
      6. egypt
      7. rest of middle east and africa
  17. Global CAR-T Cell Therapy Treatment Market: COMPANY landscape
    1. company share analysis: global
    2. company share analysis: north america
    3. company share analysis: europe
    4. company share analysis: Asia-Pacific
  18. swot analysis
  19. company profile
    1. kite pharma (A subsidiary of GILEAD SCIENCES, INC.)
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENTS
    2. Novartis AG
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENTS
    3. Abbvie inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    4. Adaptimmune Therapeutics plc
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    5. Amgen Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PIPELINE PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    6. Atara Biotherapeutics, Inc.
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    7. aurora biopharmA
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    8. Autolus
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    9. Bellicum Phamaceuticals, Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    10. BioAtla Inc.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    11. bluebird bio, inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    12. Bristol-Myers Squibb Company
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    13. carina biotech
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    14. cartherics pty ltd
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    15. cartesian therapeutics, inc.
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    16. cellectis SA
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    17. celyad oncology SA
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    18. Johnson & Johnson Services, Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    19. sorrento therapeutics, INC.
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    20. tc biopharm Limited
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    21. tessa therapeutics ltd.
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    22. tmunity therapeutics
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    23. mustang bio
      1. COMPANY SNAPSHOT
      2. PIPELINE PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    24. Xyphos (A Subsidiary of Astellas Pharma Inc.)
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PIPELINE PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    25. ziopharm oncology, inc.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
  20. questionnaire
  21. related reports

Lista de Tablas

TABLE 1 Global CAR-T cell therapy treatment Market, pipeline analysis

TABLE 2 Below provided are the alternative chemotherapies of CAR-T cell therapy:

TABLE 3 TOTAL HEALTH SPENDING BY THE U.S. (2015-2016)

TABLE 4 globaL CAR-T CELL THERAPY TREATMENTMarket, By MOLECULE, 2019-2028 (USD Million)

TABLE 5 globaL Autologous CAR-T Cells in CAR-T CELL THERAPY TREATMENTMarket, By Region, 2017-2028 (USD Million)

TABLE 6 globaL Allogeneic CAR-T Cells in CAR-T CELL THERAPY TREATMENTMARKET, By Region, 2019-2028 (USD Million)

TABLE 7 globaL CAR-T CELL THERAPY TREATMENTMarket, By Structure, 2019-2028 (USD Million)

Celyad is engaged in the manufacturing of CYAD-211, a first generation CAR-T cell therapy expressing BCMA targeting chimeric antigen receptor which interferes with the expression of the CD3ζ of T cell receptor complex. 99

TABLE 8 globaL First Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)

TABLE 9 globaL Second Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)

TABLE 10 globaL Third Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)

TABLE 11 globaL Third Generation CAR-T Cells in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)

TABLE 12 globaL CAR-T CELL THERAPY TREATMENTMarket, By targeted antigens, 2019-2028 (USD Million)

TABLE 13 globaL Antigens on Hematologic Malignancies in CAR-T CELL THERAPY TREATMENT Market, By Region, 2019-2028 (USD Million)

TABLE 14 globaL Antigens on Hematologic Malignancies in CAR-T CELL THERAPY TREATMENT Market, By Antigens on Hematologic Malignancies, 2019-2028 (USD Million)

TABLE 15 globaL Antigens on Solid Tumors in CAR-T CELL THERAPY TREATMENTMarket , By Region, 2017-2028 (USD Million)

TABLE 16 globaL Antigens on Solid Tumors in CAR-T CELL THERAPY TREATMENT Market, By Antigens on Solid Tumors, 2019-2028 (USD Million)

TABLE 17 globaL others in CAR-T CELL THERAPY TREATMENTMarket , By Region, 2017-2028 (USD Million)

TABLE 18 globaL YESCARTA in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 19 globaL YESCARTA in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 20 globaL KYMRIAH in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 21 globaL TECARTUS in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 22 globaL others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 23 globaL CAR-T cell therapy treatment Market, By therapeutic type, 2019-2028 (USD Million)

TABLE 24 globaL Follicular Lymphoma in CAR-T cell therapy treatment Market, By therapeutic type, 2017-2028 (USD Million)

TABLE 25 globaL Diffuse Large B-Cell Lymphoma in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 26 globaL ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL) in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 27 globaL Mantle Cell Lymphoma in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 28 globaL Multiple Myeloma in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 29 globaL hematologic malignancies in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 30 globaL hematologic malignancies on Solid Tumors in CAR-T CELL THERAPY TREATMENT Market, By therapeutic application, 2019-2028 (USD Million)

TABLE 31 globaL Lung Cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 32 globaL chronic lymphocytic leukemia in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 33 globaL gastric cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 34 globaL pancreatic cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 35 globaL breast cancer in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 36 globaL others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 37 globaL CAR-T cell therapy treatment Market, By END USER, 2019-2028 (USD Million)

TABLE 38 globaL hospitals in CAR-T cell therapy treatment Market, By therapeutic type, 2017-2028 (USD Million)

TABLE 39 globaL specialty clinics in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 40 globaL others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 41 globaL CAR-T cell therapy treatment Market, By distribution channel, 2019-2028 (USD Million)

TABLE 42 globaL hospital pharmacy in CAR-T cell therapy treatment Market, By distribution channel, 2017-2028 (USD Million)

TABLE 43 globaL others in CAR-T cell therapy treatment Market, By Region, 2017-2028 (USD Million)

TABLE 44 GLOBAL CAR-T cell therapy treatment MARKET, BY REGION , 2021-2028 (USD MILLION)

TABLE 45 North America CAR-T Cell Therapy Treatment Market, By Region, 2019-2028 (USD Million)

TABLE 46 North America CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 47 North America CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 48 North America CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 49 North America Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 50 North America Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 51 North America CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 52 North America CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 53 North America Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 54 North America CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 55 North America CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 56 U.S CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 57 U.S CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 58 U.S CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 59 U.S Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 60 U.S Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 61 U.S CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 62 U.S CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 63 U.S Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 64 U.S CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 65 U.S CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 66 CANADA CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 67 CANADA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 68 CANADA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 69 CANADA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 70 CANADA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 71 CANADA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 72 CANADA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 73 CANADA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 74 CANADA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 75 CANADA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 76 MEXICO CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 77 MEXICO CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 78 MEXICO CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 79 MEXICO Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 80 MEXICO Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 81 MEXICO CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 82 MEXICO CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 83 MEXICO Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 84 MEXICO CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 85 MEXICO CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 86 Europe CAR-T Cell Therapy Treatment Market, By Region, 2019-2028 (USD Million)

TABLE 87 Europe CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 88 Europe CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 89 Europe CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 90 europe Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 91 Europe Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 92 Europe CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 93 Europe CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 94 Europe Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 95 Europe CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 96 Europe CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 97 Germany CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 98 Germany CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 99 Germany CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 100 Germany Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 101 Germany Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 102 Germany CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 103 Germany CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 104 Germany Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 105 Germany CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 106 Germany CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 107 U.K CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 108 U.K CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 109 U.K CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 110 U.K Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 111 U.K Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 112 U.K CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 113 U.K CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 114 U.K Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 115 U.K CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 116 U.K CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 117 FRANCE CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 118 FRANCE CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 119 FRANCE CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 120 FRANCE Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 121 FRANCE Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 122 FRANCE CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 123 FRANCE CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 124 FRANCE Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 125 FRANCE CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 126 FRANCE CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 127 ITALY CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 128 ITALY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 129 ITALY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 130 ITALY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 131 ITALY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 132 ITALY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 133 ITALY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 134 ITALY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 135 ITALY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 136 ITALY CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 137 Spain CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 138 SPAIN CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 139 SPAIN CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 140 SPAIN Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 141 SPAIN Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 142 SPAIN CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 143 SPAIN CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 144 SPAIN Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 145 SPAIN CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 146 SPAIN CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 147 netherlands CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 148 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 149 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 150 NETHERLANDS Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 151 NETHERLANDS Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 152 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 153 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 154 NETHERLANDS Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 155 NETHERLANDS CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 156 NETHERLANDS CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 157 Russia CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 158 RUSSIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 159 RUSSIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 160 RUSSIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 161 RUSSIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 162 RUSSIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 163 RUSSIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 164 RUSSIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 165 RUSSIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 166 RUSSIA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 167 Switzerland CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 168 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 169 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 170 SWITZERLAND Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 171 SWITZERLAND Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 172 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 173 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 174 SWITZERLAND Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 175 SWITZERLAND CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 176 SWITZERLAND CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 177 belgium CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 178 BELGIUM CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 179 BELGIUM CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 180 BELGIUM Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 181 BELGIUM Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 182 BELGIUM CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 183 BELGIUM CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 184 BELGIUM Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 185 BELGIUM CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 186 BELGIUM CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 187 turkey CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 188 TURKEY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 189 TURKEY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 190 TURKEY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 191 TURKEY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 192 TURKEY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 193 TURKEY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 194 TURKEY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 195 TURKEY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 196 turkey CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 197 Austria CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 198 AUSTRIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 199 AUSTRIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 200 AUSTRIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 201 AUSTRIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 202 AUSTRIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 203 AUSTRIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 204 AUSTRIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 205 AUSTRIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 206 Austria CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 207 norway CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 208 NORWAY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 209 NORWAY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 210 NORWAY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 211 NORWAY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 212 NORWAY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 213 NORWAY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 214 NORWAY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 215 NORWAY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 216 Norway CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 217 Hungary CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 218 HUNGARY CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 219 HUNGARY CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 220 HUNGARY Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 221 HUNGARY Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 222 HUNGARY CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 223 HUNGARY CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 224 HUNGARY Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 225 HUNGARY CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 226 Hungary CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 227 Lithuania CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 228 LITHUANIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 229 LITHUANIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 230 LITHUANIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 231 LITHUANIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 232 LITHUANIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 233 LITHUANIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 234 LITHUANIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 235 LITHUANIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 236 Lithuania CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 237 Ireland CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 238 IRELAND CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 239 IRELAND CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 240 IRELAND Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 241 IRELAND Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 242 IRELAND CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 243 IRELAND CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 244 IRELAND Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 245 IRELAND CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 246 ireland CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 247 Poland CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 248 POLAND CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 249 POLAND CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 250 POLAND Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 251 POLAND Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 252 POLAND CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 253 POLAND CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 254 POLAND Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 255 POLAND CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 256 Poland CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 257 Rest of Europe CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 258 Asia-Pacific CAR-T Cell Therapy Treatment Market, By Region, 2019-2028 (USD Million)

TABLE 259 Asia-Pacific CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 260 Asia-Pacific CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 261 Asia-Pacific CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 262 Asia-Pacific Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 263 Asia-Pacific Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 264 Asia-Pacific CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 265 Asia-Pacific CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 266 Asia-Pacific Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 267 Asia-Pacific CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 268 Asia-Pacific CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 269 Japan CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 270 Japan CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 271 Japan CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 272 Japan Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 273 Japan Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 274 Japan CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 275 Japan CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 276 Japan Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 277 Japan CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 278 Japan CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 279 AUSTRALIA CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 280 AUSTRALIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 281 AUSTRALIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 282 AUSTRALIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 283 AUSTRALIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 284 AUSTRALIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 285 AUSTRALIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 286 AUSTRALIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 287 AUSTRALIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 288 AUSTRALIA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 289 SINGAPORE CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 290 SINGAPORE CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 291 SINGAPORE CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 292 SINGAPORE Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 293 SINGAPORE Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 294 SINGAPORE CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 295 SINGAPORE CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 296 SINGAPORE Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 297 SINGAPORE CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 298 SINGAPORE CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 299 CHINA CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 300 CHINA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 301 CHINA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 302 CHINA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 303 CHINA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 304 CHINA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 305 CHINA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 306 CHINA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 307 CHINA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 308 CHINA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 309 South Korea CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 310 SOUTH KOREA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 311 SOUTH KOREA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 312 SOUTH KOREA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 313 SOUTH KOREA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 314 SOUTH KOREA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 315 SOUTH KOREA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 316 SOUTH KOREA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 317 SOUTH KOREA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 318 SOUTH KOREA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 319 India CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 320 INDIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 321 INDIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 322 INDIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 323 INDIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 324 INDIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 325 INDIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 326 INDIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 327 INDIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 328 INDIA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 329 Malaysia CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 330 MALAYSIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 331 MALAYSIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 332 MALAYSIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 333 MALAYSIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 334 MALAYSIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 335 MALAYSIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 336 MALAYSIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 337 MALAYSIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 338 MALAYSIA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 339 Thailand CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 340 THAILAND CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 341 THAILAND CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 342 THAILAND Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 343 THAILAND Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 344 THAILAND CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 345 THAILAND CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 346 THAILAND Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 347 THAILAND CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 348 THAILAND CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 349 Indonesia CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 350 iNDONESIA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 351 INDONESIA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 352 INDONESIA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 353 INDONESIA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 354 INDONESIA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 355 INDONESIA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 356 INDONESIA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 357 INDONESIA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 358 INDONESIA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 359 Philippines CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 360 PHILIPPINES CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 361 PHILIPPINES CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 362 PHILIPPINES Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 363 PHILIPPINES Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 364 PHILIPPINES CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 365 PHILIPPINES CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 366 PHILIPPINES Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 367 PHILIPPINES CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 368 Philippines CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 369 Vietnam CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 370 VIETNAM CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 371 VIETNAM CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 372 VIETNAM Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 373 VIETNAM Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 374 VIETNAM CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 375 VIETNAM CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 376 VIETNAM Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 377 VIETNAM CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 378 Vietnam CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 379 Rest of Asia-Pacific CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 380 South AMERICA CAR-T Cell Therapy Treatment Market, By Region, 2019-2028 (USD Million)

TABLE 381 SOUTH AMERICA CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 382 SOUTH AMERICA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 383 SOUTH AMERICA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 384 SOUTH AMERICA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 385 SOUTH AMERICA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 386 SOUTH AMERICA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 387 SOUTH AMERICA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 388 SOUTH AMERICA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 389 SOUTH AMERICA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 390 SOUTH AMERICA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 391 BRAZIL CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 392 BRAZIL CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 393 BRAZIL CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 394 BRAZIL Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 395 BRAZIL Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 396 BRAZIL CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 397 BRAZIL CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 398 BRAZIL Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 399 BRAZIL CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 400 BRAZIL CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 401 ARGENTINA CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 402 ARGENTINA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 403 ARGENTINA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 404 ARGENTINA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 405 ARGENTINA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 406 ARGENTINA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 407 ARGENTINA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 408 ARGENTINA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 409 ARGENTINA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 410 ARGENTINA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 411 PERU CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 412 peru CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 413 peru CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 414 peru Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 415 peru Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 416 peru CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 417 peru CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 418 peru Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 419 peru CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 420 peru CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 421 REST OF SOUTH AMERICA CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 422 Middle East and Africa CAR-T Cell Therapy Treatment Market, By Region, 2019-2028 (USD Million)

TABLE 423 Middle East and Africa CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 424 Middle East and Africa CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 425 Middle East and Africa CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 426 Middle East and Africa Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 427 Middle East and Africa Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 428 Middle East and Africa CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 429 Middle East and Africa CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 430 Middle East and Africa Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 431 Middle East and Africa CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 432 Middle East and Africa CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 433 Saudi Arabia CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 434 Saudi Arabia CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 435 Saudi Arabia CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 436 Saudi Arabia Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 437 Saudi Arabia Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 438 Saudi Arabia CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 439 Saudi Arabia CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 440 Saudi Arabia Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 441 Saudi Arabia CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 442 Saudi Arabia CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 443 UAE CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 444 UAE CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 445 UAE CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 446 UAE Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 447 UAE Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 448 UAE CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 449 UAE CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 450 UAE Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 451 UAE CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 452 UAE CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 453 SOUTH AFRICA CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 454 SOUTH AFRICA CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 455 SOUTH AFRICA CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 456 SOUTH AFRICA Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 457 SOUTH AFRICA Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 458 SOUTH AFRICA CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 459 SOUTH AFRICA CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 460 SOUTH AFRICA Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 461 SOUTH AFRICA CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 462 SOUTH AFRICA CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 463 ISRAEL CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 464 ISRAEL CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 465 ISRAEL CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 466 ISRAEL Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 467 ISRAEL Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 468 ISRAEL CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 469 ISRAEL CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 470 ISRAEL Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 471 ISRAEL CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 472 ISRAEL CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 473 KUWAIT CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 474 KUWAIT CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 475 KUWAIT CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 476 KUWAIT Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 477 KUWAIT Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 478 KUWAIT CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 479 KUWAIT CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 480 KUWAIT Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 481 KUWAIT CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 482 KUWAIT CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 483 EGYPT CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

TABLE 484 EGYPT CAR-T Cell Therapy Treatment Market, By Structure 2019-2028 (USD Million)

TABLE 485 EGYPT CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 486 EGYPT Antigens on Hematologic Malignancies in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 487 EGYPT Antigens on Solid Tumors in CAR-T Cell Therapy Treatment Market, By Targeted Antigens, 2019-2028 (USD Million)

TABLE 488 EGYPT CAR-T Cell Therapy Treatment Market, By Brand, 2019-2028 (USD Million)

TABLE 489 EGYPT CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 490 EGYPT Hematologic malignancies in CAR-T Cell Therapy Treatment Market, By Therapeutic Application, 2019-2028 (USD Million)

TABLE 491 EGYPT CAR-T Cell Therapy Treatment Market, By End User, 2019-2028 (USD Million)

TABLE 492 EGYPT CAR-T Cell Therapy Treatment Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 493 EGYPT CAR-T Cell Therapy Treatment Market, By Product, 2019-2028 (USD Million)

Lista de figuras

FIGURE 1 Global CAR-T cell therapy treatment MARKET: SEGMENTATION

FIGURE 2 GLOBAL CAR-T cell therapy treatment MARKET: DATA TRIANGULATION

FIGURE 3 global CAR-T cell therapy treatment Market: DROC ANALYSIS

FIGURE 4 Global CAR-T cell therapy treatment market: Global VS REGIONAL MARKET ANALYSIS

FIGURE 5 Global CAR-T cell therapy treatment Market: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL CAR-T cell therapy treatment MARKET: MULTIVARIATE MODELLING

FIGURE 7 GLOBAL CAR-T cell therapy treatment MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 GLOBAL CAR-T cell therapy treatment MARKET: DBMR MARKET POSITION GRID

FIGURE 9 GLOBAL CAR-T cell therapy treatment MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL car-t cell therapy treatment MARKET: MARKET product COVERAGE GRID

FIGURE 11 Global car-t cell therapy treatment market: SEGMENTATION

FIGURE 12 NORTH AMERICA is expected to DOMINATE THE GLOBAL CAR-T cell therapy treatment market AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 increasing investment in research and development is expected to drive THE global CAR-T cell therapy treatment market IN THE FORECAST PERIOD OF 2021 to 2028

FIGURE 14 Autologus car-t cells SEGMENT is expected to account for the largest share of the global CAR-T CELL THERAPY TREATMENT market in 2021 & 2028

FIGURE 15 ASIA-PACIFIC is the fastest growing market FOR the CAR-T cell therapy treatment MANUFACTURERS IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGEs OF Global CAR-T cell therapy treatment Market

FIGURE 17 New Cancer Cases Worldwide, (2018)

FIGURE 18 Global Cancer Incidence (2018)

FIGURE 19 Cancer Death By Type (in million), world, 2017

FIGURE 20 global CAR-T CELL THERAPY TREATMENTmarket: BY Product, 2021

FIGURE 21 global CAR-T CELL THERAPY TREATMENTmarket: BY Product, 2019-2028 (USD Million)

FIGURE 22 global CAR-T CELL THERAPY TREATMENTmarket: BY Product, CAGR (2021-2028)

FIGURE 23 global CAR-T CELL THERAPY TREATMENTmarket: BY Product, LIFELINE CURVE

FIGURE 24 global CAR-T CELL THERAPY TREATMENTmarket: BY structure, 2021

FIGURE 25 global CAR-T CELL THERAPY TREATMENTmarket: BY structure, 2019-2028 (USD Million)

FIGURE 26 global CAR-T CELL THERAPY TREATMENTmarket: BY structure, CAGR (2021-2028)

FIGURE 27 global CAR-T CELL THERAPY TREATMENTmarket: BY structure, LIFELINE CURVE

FIGURE 28 global CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, 2021

FIGURE 29 global CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, 2019-2028 (USD Million)

FIGURE 30 global CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, CAGR (2021-2028)

FIGURE 31 global CAR-T CELL THERAPY TREATMENTmarket: BY targeted antigens, LIFELINE CURVE

FIGURE 32 global CAR-T cell therapy treatment market: BY brand, 2020

FIGURE 33 global CAR-T cell therapy treatment market: BY brand, 2020-2028 (USD Million)

FIGURE 34 global CAR-T cell therapy treatment market: BY brand, CAGR (2020-2028)

FIGURE 35 global CAR-T cell therapy treatment market: BY brand, LIFELINE CURVE

FIGURE 36 global CAR-T cell therapy treatment market: BY therapeutic application, 2020

FIGURE 37 global CAR-T cell therapy treatment market: BY therapeutic application, 2020-2028 (USD Million)

FIGURE 38 global CAR-T cell therapy treatment market: BY therapeutic application, CAGR (2020-2028)

FIGURE 39 global CAR-T cell therapy treatment market: BY therapeutic application, LIFELINE CURVE

FIGURE 40 global CAR-T cell therapy treatment market: BY END USER, 2020

FIGURE 41 global CAR-T cell therapy treatment market: BY END USER, 2020-2028 (USD Million)

FIGURE 42 global CAR-T cell therapy treatment market: BY END USER, CAGR (2020-2028)

FIGURE 43 global CAR-T cell therapy treatment market: BY END USER, LIFELINE CURVE

FIGURE 44 global CAR-T cell therapy treatment market: BY distribution channel, 2020

FIGURE 45 global CAR-T cell therapy treatment market: BY distribution channel, 2020-2028 (USD Million)

FIGURE 46 global CAR-T cell therapy treatment market: BY distribution channel, CAGR (2020-2028)

FIGURE 47 global CAR-T cell therapy treatment market: BY distribution channel, LIFELINE CURVE

FIGURE 48 GLOBAL CAR-T cell therapy treatment market: SNAPSHOT (2020)

FIGURE 49 GLOBAL CAR-T cell therapy treatment market: BY COUNTRY (2020)

FIGURE 50 GLOBAL CAR-T cell therapy treatment market: BY COUNTRY (2021 & 2028)

FIGURE 51 GLOBAL CAR-T cell therapy treatment market: BY COUNTRY (2020 & 2028)

FIGURE 52 GLOBAL CAR-T cell therapy treatment market: BY PRODUCT (2021-2028)

FIGURE 53 North America CAR-T CELL THERAPY TREATMENT market: SNAPSHOT (2020)

FIGURE 54 North America CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020)

FIGURE 55 North America CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2021 & 2028)

FIGURE 56 North America CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020 & 2028)

FIGURE 57 North America CAR-T CELL THERAPY TREATMENT market: BY product (2021-2028)

FIGURE 58 Europe CAR-T CELL THERAPY TREATMENT market: SNAPSHOT (2020)

FIGURE 59 Europe CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020)

FIGURE 60 Europe CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2021 & 2028)

FIGURE 61 Europe CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020 & 2028)

FIGURE 62 Europe CAR-T CELL THERAPY TREATMENT market: BY product (2021-2028)

FIGURE 63 Asia-Pacific CAR-T CELL THERAPY TREATMENT market: SNAPSHOT (2020)

FIGURE 64 Asia-Pacific CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020)

FIGURE 65 Asia-Pacific CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2021 & 2028)

FIGURE 66 Asia-Pacific CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020 & 2028)

FIGURE 67 Asia-Pacific CAR-T CELL THERAPY TREATMENT market: BY product (2021-2028)

FIGURE 68 South America CAR-T CELL THERAPY TREATMENT market: SNAPSHOT (2020)

FIGURE 69 South America CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020)

FIGURE 70 South America CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2021 & 2028)

FIGURE 71 South America CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020 & 2028)

FIGURE 72 South America CAR-T CELL THERAPY TREATMENT market: BY product (2021-2028)

FIGURE 73 Middle East and Africa CAR-T CELL THERAPY TREATMENT market: SNAPSHOT (2020)

FIGURE 74 Middle East and Africa CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020)

FIGURE 75 Middle East and Africa CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2021 & 2028)

FIGURE 76 Middle East and Africa CAR-T CELL THERAPY TREATMENT market: BY COUNTRY (2020 & 2028)

FIGURE 77 Middle East and Africa CAR-T CELL THERAPY TREATMENT market: BY product (2021-2028)

FIGURE 78 Global CAR-T Cell Therapy Treatment market: company share 2020 (%)

FIGURE 79 North America CAR-T Cell Therapy Treatment Market: company share 2020 (%)

FIGURE 80 EUROPE CAR-T Cell Therapy Treatment Market: company share 2020 (%)

FIGURE 81 ASIA-PACIFIC CAR-T Cell Therapy Treatment Market: company share 2020 (%)

Ver información detallada Right Arrow

Metodología de investigación

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.

La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.

Personalización disponible

Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados ​​en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.

Preguntas frecuentes

The growth rate of the CAR-T cell therapy treatment market is 32.3% in the forecast by 2030.
North America is dominating in the CAR-T cell therapy treatment market.
Product, structure, targeted antigens, brand, therapeutic application, end-user and distribution channel are the factors on which the CAR-T cell therapy treatment market research is based.
Major companies in the CAR-T cell therapy treatment market are Autolus (U.K.), Atara Biotherapeutics, Inc. (U.S.), Amgen Inc. (U.S.), Bellicum Phamaceuticals, Inc. (U.S.), bluebird bio, Inc. (U.S.), Adaptimmune Therapeutics plc (U.K.), Bristol-Myers Squibb Company (U.S.), Xyphos (a subsidiary of Astellas Pharma Inc.) (U.S.), Johnson & Johnson Services, Inc. (U.S.), BioAtla Inc. (U.S.), AbbVie Inc. (U.S.), Novartis AG (Switzerland), Kite Pharma (a subsidiary of Gilead Sciences, Inc.) (U.S.), Aurora Biopharma (U.S.), Tmunity Therapeutics (U.S.), Cartherics pty. Ltd (Australia), CARINA BIOTECH (Australia), Ziopharm Oncology, Inc. (U.S.), Cellectis SA (France), Mustang Bio (U.S.), Sorrento Therapeutics, Inc. (U.S.), Cartesian Therapeutics, Inc. (U.S.), TC BioPharm Limited (U.K.), Celyad Oncology SA (Belgium), Tessa Therapeutics Ltd. (Singapore),
Growing prevalence of targeted therapies, rising technological advancements & increasing funding by public private authorities are the growth drivers of the CAR-T cell therapy treatment market.

Explorar páginas relacionadas

Banner